NCT05266105View on ClinicalTrials.gov

A Phase 1 Study of Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer Patients

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

December 10, 2021

Primary Completion Date

January 31, 2025

Study Completion Date

July 31, 2025

Conditions
Breast Cancer
Interventions
DRUG

Palazestrant

Complete Estrogen Receptor Antagonist

DRUG

Palbociclib

Palbociclib is an approved CDK 4/6 Inhibitor drug

Trial Locations (8)

2145

Site 6104, Westmead

2298

Site 6108, Waratah

3168

Site 6101, Clayton

3199

Site 6106, Frankston

3220

Site 6103, Geelong

4101

Site 6102, South Brisbane

4215

Site 6109, Southport

6009

Site 6105, Nedlands

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Olema Pharmaceuticals, Inc.

INDUSTRY